Party Branch of Peak Pharmaceutical Organs Held Democratic Life Meeting
Release time:
2021-04-12
and April 7 26 . It is understood that due to the large number of personnel in the Party branch of the pharmaceutical department and the three working places of the headquarters, Jinxi and Qiubin, it is not convenient for the Party branch to organize centralized learning and activities. Therefore, in order to improve the effectiveness of party members' activities and minimize the impact on their own work, the party branch of the pharmaceutical department set up two party groups in this year. the first party group includes members of the pharmaceutical department and the development department working in qiubin factory. The second party group includes members of the quality department and the second manufacturing department (formerly the internationalization project) working in Jinxi factory. At the democratic life meeting of the second party group held on 25 , each party member spoke enthusiastically based on the principle of seeking truth from facts, took the initiative to expose problems, carried out criticism and self-criticism, and comprehensively improved the physical and mental quality and political accomplishment of each party member through the form of
"blushing and sweating " . After full communication and exchange of opinions, everyone further unified their thinking and understanding, and clarified the goal of comprehensively improving themselves in work and study in the future. Dai Jinxiao, member of the Party Committee of the Pharmaceutical Company and secretary of the Party branch of the organ, further publicized the working ideas and key points of the Party Committee of the Group Company in 2021
, and hoped that all Party members could actively participate in the"Learning Party History and Celebrating Centennial " activities. At the democratic life meeting of the first party group held on the 29th, the members of the group conducted in-depth analysis according to the main contents and requirements of the meeting, combined with work, study, life and other aspects, to find out the reasons, to find out the gaps, and to analyze themselves, sum up experiences and lessons, and conduct self-criticism on the basis of solving problems and contradictions. Huang Jinlong, secretary of the pharmaceutical party committee, and Dai Jinxiao, deputy secretary of the party committee, also criticized themselves in terms of political theory study, performance of work system responsibilities, enterprise innovation and development, and branch construction. Huang Jinlong emphasized that the normalization of the branch organization life meeting is an important content for implementing the requirements of the group party committee. It is a powerful starting point for improving the ideological awareness and learning level of each party member. Only by constantly summing up oneself and self in work and life Only by criticizing can we find gaps and make progress. (Liao Lisa Song Shijie)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page